Vemurafenib + rituximab for relapsed/refractory BRAF-V600E HCL

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-RITUXIMAB`

ID	`REG-VEMURAFENIB-HCL-RELAPSED`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-MOZ-UA-LYMPH-2013` `SRC-NCCN-BCELL-2025`

Notes

Tiacci 2021 (NEJM): vemurafenib + rituximab in r/r HCL — CR ~87%, MRD-negative ~65%. NCCN-preferred 2L for BRAF-V600E HCL (~95% of classic HCL). Drug entity for vemurafenib not yet in KB — flagged for promotion when broader BRAF coverage opens.

Used By

Indication

IND-HCL-2L-VEMURAFENIB - IND-HCL-2L-VEMURAFENIB